The effect of Astragalus membranaceus on Caenorhabditis elegans was assessed in this experiment. Parkinson’s Disease directly causes dopamine depletion and other related symptoms. Astragalus contains complex carbohydrates linked to dopamine neuron protection, which could be used to treat Parkinson’s. In this experiment, C.elegans inflicted with Parkinson’s were treated with different concentrations of Astragalus. C.elegans are free-living nematodes that can be genetically engineered to model or stimulate various diseases caused by genetics, Parkinson’s being one of them. The concentrations of astragalus solution were 2 mg/mL, 4 mg/mL, and 8 mg/mL, which were added to the agar that the C.elegans inhabited. Mechanosensory tests included tap reflex and gentle and harsh touch assessment. M9 Buffer was used to inhibit the egg-laying behaviors of C.elegans, and the thrashing rate was assessed for each group. The results indicate that 4 mg/mL is the optimal concentration to treat disease-inflicted C.elegans and had the best results out of the 3 trials. The 4 mg/mL group constantly had the highest tap reflex, gentle, and harsh touch scores that were similar or greater than the wild-type control group. Additionally, the 2 mg/mL also had high scores in trials 2 and 3 in both the gentle The Effect of Astragalus membranaceus Root Extract on Parkinson Inflicted Caenorhabditis elegans Jun Lin, Donato Massimo Brogna, Omar Chaudhry and harsh touch assessments. No definite conclusions can be determined from thrashing rate data. The results imply that lower and intermediate concentrations of Astragalus may treat the symptoms of Parkinson’s Disease.

References

1. Altun, Z. F., & Hall, D. H. (2009). Introduction. In WormAtlas. https://doi.org/10.3908/wormatlas.1.1
2. Anjaneyulu, J., R, V., & Godbole, A. (2020). Differential effect of Ayurvedic nootropics on C. elegans models of Parkinson's disease. Journal of Ayurveda and Integrative Medicine, 11(4), 440–447. https://doi.org/10.1016/j.jaim.2020.07.006
3. Apfeld, J., & Alper, S. (2018). What can we learn about human disease from the nematode C. elegans? In Disease Gene Identification (pp. 53–75). https://doi.org/10.1007/978-1-4939-7471-9_4
4. Baugh, L. R., & Hu, P. J. (2020). Starvation responses throughout the Caenorhabditis elegans life cycle. Genetics, 216(4), 837–878. https://doi.org/10.1534/genetics.120.303565
5. Bodhicharla, R., Nagarajan, A., Winter, J., Adenle, A., Nazir, A., Brady, D., et al. (2012). Effects of α-synuclein overexpression in transgenic Caenorhabditis elegans strains. CNS & Neurological Disorders-Drug Targets, 11(8), 965–975. https://doi.org/10.2174/1871527311211080005
6. Cooper, J. F., & Van Raamsdonk, J. M. (2018). Modeling Parkinson’s disease in C. elegans. Journal of Parkinson's Disease, 8(1), 17–32. https://doi.org/10.3233/JPD-171258
7. Chalfie, M., & Sulston, J. (1981). Developmental genetics of the mechanosensory neurons of Caenorhabditis elegans. Developmental Biology, 82(2), 358–370. https://doi.org/10.1016/0012-1606(81)90459-0
8. Di Rosa, G., Brunetti, G., Scuto, M., Trovato Salinaro, A., Calabrese, E. J., Crea, R., et al. (2020). Healthspan enhancement by olive polyphenols in C. elegans wild type and Parkinson’s models. International Journal of Molecular Sciences, 21(11), 3893. https://doi.org/10.3390/ijms21113893
9. Dias, V., Junn, E., & Mouradian, M. M. (2013). The role of oxidative stress in Parkinson's disease. Journal of Parkinson's Disease, 3(4), 461–491. https://doi.org/10.3233/JPD-130230
10. Filograna, R., Beltramini, M., Bubacco, L., & Bisaglia, M. (2016). Anti-oxidants in Parkinson’s disease therapy: A critical point of view. Current Neuropharmacology, 14(3), 260–271. https://doi.org/10.2174/1570159X13666151030102718
11. Ghosh, N., Ghosh, R., & Mandal, S. C. (2011). Antioxidant protection: A promising therapeutic intervention in neurodegenerative disease. Free Radical Research, 45(8), 888–905. https://doi.org/10.3109/10715762.2011.574290
12. Guo, J. D., Zhao, X., Li, Y., Li, G. R., & Liu, X. L. (2018). Damage to dopaminergic neurons by oxidative stress in Parkinson's disease. International Journal of Molecular Medicine, 41(4), 1817–1825. https://doi.org/10.3892/ijmm.2018.3406
13. Huang, W. M., Liang, Y. Q., Tang, L. J., Ding, Y., & Wang, X. H. (2013). Antioxidant and anti-inflammatory effects of Astragalus polysaccharide on EA.hy926 cells. Experimental and Therapeutic Medicine, 6(1), 199–203. https://doi.org/10.3892/etm.2013.1074
14. Johnson, W. M., Wilson-Delfosse, A. L., & Mieyal, J. J. (2012). Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients, 4(10), 1399–1440. https://doi.org/10.3390/nu4101399
15. LeWitt, P. A. (2008). Levodopa for the treatment of Parkinson's disease. New England Journal of Medicine, 359(23), 2468–2476. https://doi.org/10.1056/NEJMct0800326
16. Li, H., Shi, R., Ding, F., Wang, H., Han, W., Ma, F., et al. (2016). Astragalus polysaccharide suppresses 6-hydroxydopamine-induced neurotoxicity in Caenorhabditis elegans. Oxidative Medicine and Cellular Longevity, 2016. https://doi.org/10.1155/2016/4856761
17. Liu, H., Chen, S., Guo, C., Tang, W., Liu, W., & Liu, Y. (2018). Astragalus polysaccharide protects neurons and stabilizes mitochondria in a mouse model of Parkinson disease. Medical Science Monitor, 24, 5192–5201. https://doi.org/10.12659/MSM.908021
18. Maulik, M., Mitra, S., Bult-Ito, A., Taylor, B. E., & Vayndorf, E. M. (2017). Behavioral phenotyping and pathological indicators of Parkinson's disease in C. elegans models. Frontiers in Genetics, 8, 77.
19. Oertel, W., & Schulz, J. B. (2016). Current and experimental treatments of Parkinson disease: A guide for neuroscientists. Journal of Neurochemistry, 139, 325–337.
20. Sanyal, S., Wintle, R. F., Kindt, K. S., Nuttley, W. M., Arvan, R., Fitzmaurice, P., et al. (2004). Dopamine modulates the plasticity of mechanosensory responses in Caenorhabditis elegans. The EMBO Journal, 23(2), 473–482.
21. Sekeroglu, N., & Gezici, S. (2019). Astragalus neurocarpus Bioss. as a potential source of natural enzyme inhibitor associated with Alzheimer’s and Parkinson diseases along with its rich polyphenolic content and antioxidant activities. Annals of Phytomedicine, 8(1), 82–87. https://doi.org/10.21276/ap.2019.8.1.9
22. Scheider, W. L., Hershey, L. A., Vena, J. E., Holmlund, T., Marshall, J. R., & Freudenheim, J. L. (1997). Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Movement Disorders, 12(2), 190–196. https://doi.org/10.1002/mds.870120209
23. Singh, N., Pillay, V., & Choonara, Y. E. (2007). Advances in the treatment of Parkinson's disease. Progress in Neurobiology, 81(1), 29–44. https://doi.org/10.1016/j.pneurobio.2006.11.009
24. Parkinson's Foundation. (n.d.). Statistics. Retrieved January 27, 2022, from https://www.parkinson.org/Understanding-Parkinsons/Statistics
25. Stiernagle, T. (2006). Maintenance of C. elegans. WormBook. https://doi.org/10.1895/wormbook.1.101.1
26. Tohda, C., Tamura, T., Matsuyama, S., & Komatsu, K. (2006). Promotion of axonal maturation and prevention of memory loss in mice by extracts of Astragalus mongholicus. British Journal of Pharmacology, 149(5), 532–541. https://doi.org/10.1038/sj.bjp.0706865
27. U.S. Department of Health and Human Services. (n.d.). Parkinson's disease. National Institute on Aging. Retrieved January 27, 2022, from https://www.nia.nih.gov/health/parkinsons-disease
28. Yu, J., Ji, H. Y., & Liu, A. J. (2018). Alcohol-soluble polysaccharide from Astragalus membranaceus: Preparation, characteristics, and antitumor activity. International Journal of Biological Macromolecules, 118, 2057–2064. https://doi.org/10.1016/j.ijbiomac.2018.07.073
29. Zhang, B., Xiao, R., Ronan, E. A., He, Y., Hsu, A. L., Liu, J., & Xu, X. S. (2015). Environmental temperature differentially modulates C. elegans longevity through a thermosensitive TRP channel. Cell Reports, 11(9), 1414–1424. https://doi.org/10.1016/j.celrep.2015.04.066
30. Zheng, Y., Ren, W., Zhang, L., Zhang, Y., Liu, D., & Liu, Y. (2020). A review of the pharmacological action of Astragalus polysaccharide. Frontiers in Pharmacology, 11, 349. https://doi.org/10.3389/fphar.2020.00349